Skip to main content

Advertisement

SpringerLink
Log in

Pericardial fat in type 2 diabetes: not just a biomarker, but a promising treatment target?

  • Letter to the Editor
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

The Original Article was published on 20 December 2019

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Nafakhi H, Al-Mosawi AA, Mudhafar MM (2019) Pericardial fat versus BMI in the assessment of coronary atherosclerotic burden in patients with diabetes mellitus. Acta Diabetol. https://doi.org/10.1007/s00592-019-01465-9

    Article  PubMed  Google Scholar 

  2. Zsóri G, Illés D, Ivány E et al (2019) In new-onset diabetes mellitus, metformin reduces fat accumulation in the liver, but not in the pancreas or pericardium. Metab Syndr Relat Disord 17(5):289–295

    Article  Google Scholar 

  3. Jonker JT, Lamb HJ, van der Meer RW et al (2010) Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 95(1):456–460

    Article  CAS  Google Scholar 

  4. Hsu JC, Wang CY, Su MM, Lin LY, Yang WS (2019) Effect of empagliflozin on cardiac function, adiposity, and diffuse fibrosis in patients with type 2 diabetes mellitus. Sci Rep 9(1):1534

    Article  Google Scholar 

  5. Christensen RH, von Scholten BJ, Hansen CS et al (2019) Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes. Cardiovasc Diabetol 18(1):114

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Second Propedeutic Department of Internal Medicine, General Hospital “Hippokration”, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642, Thessaloníki, Greece

    Dimitrios Patoulias & Michael Doumas

  2. Third Department of Cardiology, General Hospital “Hippokration”, Aristotle University of Thessaloniki, Thessaloníki, Greece

    Christodoulos Papadopoulos

  3. Veterans Affairs Medical Center, George Washington University, Washington, DC, USA

    Michael Doumas

Authors
  1. Dimitrios Patoulias
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christodoulos Papadopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Doumas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dimitrios Patoulias.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Not required for this type of manuscript.

Human and animal rights

This manuscript does not contain any human or animal studies performed by any of the authors.

Informed consent

For this type of study, formal consent was not necessary.

Additional information

Managed by Massimo Porta.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patoulias, D., Papadopoulos, C. & Doumas, M. Pericardial fat in type 2 diabetes: not just a biomarker, but a promising treatment target?. Acta Diabetol 57, 905–906 (2020). https://doi.org/10.1007/s00592-020-01478-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-020-01478-9

Search

Navigation